Could 3 radiation doses beat 4 for cervical cancer?
NCT ID NCT07022470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a shorter course of brachytherapy (3 sessions) to the standard 4-session regimen for locally advanced cervical cancer. About 41 participants will receive either 3 or 4 high-dose radiation treatments based on what is feasible for them. The goal is to see if the shorter schedule is practical and still controls the disease effectively.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- radiation (brachytherapy)
- What this could lead to
- If successful, this could show that fewer radiation sessions are enough to control cervical cancer, making treatment shorter and more convenient.
- What could go wrong
- This is a small, early-phase trial with only 41 participants, so results may not apply to everyone. The 3-fraction schedule might not control the cancer as well as the standard 4-fraction regimen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 41 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically documented malignancy of the cervix and planned to receive brachytherapy as part of definitive treatment. * ECOG performance status of 0-2 * Age ≥ 18 years old. * Ability to understand and the willingness to provide written informed consent. Exclusion Criteria: * Contraindication to receiving radiotherapy as determined by treating radiation oncologist. * Contraindication to receiving MRI. * Prior radiation to the pelvis \> 3 months ago * Age \< 18 years old. * Pregnant or breast-feeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancers are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a condensed radiation course after cervical cancer surgery be just as safe and effective?
- Nurse navigators boost cervical cancer screening in study
- At-Home HPV tests could boost cervical cancer screening in border communities
- Rare surgery for recurrent cancer: how does it affect quality of life?
- Can a Nurse-Led program transform Women's health in hong kong?
- New hope for advanced cancers: experimental drug XNW28012 enters human trials